Non-Human Primate (NHP) Applications

Q: How do you compare the advantages of NHPs to other models, such as rodents or in vitro systems?

While in vitro systems and rodent models are valuable for early-stage screening, NHPs are a critical next step due to their closer genetic and physiological resemblance to humans. This allows for a more accurate assessment of a drug's safety and efficacy, particularly for complex systemic effects and gene therapy applications, significantly reducing the risk of unexpected results in human trials.

Are you currently facing complex challenges in your preclinical research, such as the need for accurate translational data for novel drug modalities? Our Creative Biolabs NHP models have multiple applications, providing high-quality, clinically relevant data through advanced NHP models. Leveraging our deep biological expertise, we enable you to obtain the critical insights needed to move your therapeutic candidates toward clinical trials with confidence.

Non-Human Primate Models for Advanced Drug Development

Non-human primate models provide essential translational data for advanced therapeutic modalities, enabling the de-risking of novel drug candidates and ensuring data required for regulatory submissions.

Get a Quote

Overview of NHP Applications

What Are Our Research Areas?

Our NHP application focus on providing comprehensive preclinical research support for a range of advanced therapeutic modalities. We specialize in developing and utilizing relevant NHP models that closely mimic human physiology and disease pathology. Our research services are designed to address critical questions across the entire preclinical research continuum, from early-stage proof-of-concept studies to formal regulatory toxicology and safety assessments.

By Therapeutic Modalities: Our expertise spans a wide range of modalities, including small molecules, biopharmaceuticals (monoclonal antibodies, fusion proteins), gene therapies (AAV, lentiviral vectors), cell therapies (CAR-T, stem cells), and vaccines.
By Disease Areas: We provide robust support for research in key disease areas such as infectious diseases (including HIV/AIDS, Zika, and emerging viral threats), neuroscience (Alzheimer's, Parkinson's, psychiatric disorders), oncology, and rare genetic diseases.
By Research Stage: We offer support for various research stages, including target validation, efficacy studies, PK/PD (pharmacokinetics/pharmacodynamics) evaluation, and IND-enabling safety and toxicology studies.

Why Choose NHPs?

NHPs offer unique and often indispensable advantages that cannot be fully replicated by other animal models. Choosing Creative Biolabs' NHP services provides you with:

Genetic and Immunological Similarities: NHPs possess a high degree of genetic, physiological, and immunological homology with humans, making them the most predictive models for studying human diseases and testing new therapies.
Clinical Translational Relevance: Data obtained from NHP models is highly translatable to the clinical setting, providing a strong foundation for predicting human response to a therapeutic candidate.
Data Types Required for Regulatory Submissions: Regulatory bodies often require data from a relevant non-rodent species, with NHPs being a preferred choice for many advanced therapies, particularly for assessing safety and biodistribution.

Key Applications of NHPs

Our NHP models are critical for a wide range of applications, providing the detailed insights necessary to move your project forward.

Gene Therapy Biodistribution and Safety: NHPs are the gold standard for studying the in vivo biodistribution of viral vectors like AAVs, assessing vector shedding, and evaluating potential toxicity. These studies provide crucial data for regulatory submissions and help ensure patient safety.
Modeling Neurodegenerative and Psychiatric Disorders: NHPs are invaluable for investigating complex neurological diseases. Their intricate brain morphology and social complexity allow for the study of psychiatric illnesses as they are expressed within a complex social environment, providing a more holistic understanding of a drug's effect on behavior and cognition.
Vaccine and Antiviral Development: Due to their susceptibility to many human pathogens, NHPs are essential for evaluating the efficacy and safety of novel vaccines and antiviral drugs, helping to accelerate the development of critical countermeasures for infectious diseases like HIV, Zika, and Ebola.
Oncology and Immuno-Oncology Research: NHP models are used to study the tumor microenvironment and evaluate the efficacy of complex immunotherapies, such as CAR-T and checkpoint inhibitors. They provide critical data on immune responses and potential cytokine release syndrome (CRS) that cannot be accurately replicated in other species.

How Do Creative Biolabs Support Your Projects?

At Creative Biolabs, we don't just provide a model; we offer a complete solution. We translate your research needs into a comprehensive, data-driven strategy.

Gene Therapy

Expert support for AAV vector studies and gene editing technologies.
Explore Services > DMPK & PK/PD Evaluation

Neuroscience

Advanced models for studying neurological and psychiatric disorders.
Explore Services > Pharmacology & Efficacy

Vaccine & Antiviral

Comprehensive platforms for infectious disease research and vaccine efficacy.
Explore Services > Safety & Toxicology

Oncology

Specialized models for immuno-oncology and tumor microenvironment studies.
Explore Services > Disease Model Development

We are ready to support your research with our scientifically rigorous approach. Contact us today to discuss your project and discover how our services can streamline your path to the clinic.

Translational Impact

More reliable early proof of concept: NHP models provide data that is highly predictive of human response, helping clients make informed go/no-go decisions early in the development process.
Early detection of potential issues: These models facilitate the early identification of potential immune responses or toxicities, which can prevent costly and time-consuming failures during IND (Investigational New Drug) submissions.
Reduced risk of IND failure: By providing critical safety and biodistribution data that is often required by regulatory agencies, NHP models serve as an essential step toward regulatory approval.
Essential for specific regulatory requirements: For advanced therapies like gene therapy, NHP biodistribution and safety data are explicitly required by regulatory agencies, making this a crucial and necessary step in the research journey.

Frequently Asked Questions

Q: What is the resolution and sensitivity of the data from your NHP models?

A: Our advanced imaging and analytical platforms provide high-resolution and high-sensitivity data. For instance, our quantitative biodistribution studies can detect and measure vector genomes with exceptional precision, providing you with the robust data needed for regulatory submissions.

Q: What cell sources are used in your NHP models, and what is the sample stability?

A: We utilize a variety of ethically-sourced NHP models with well-defined genetic backgrounds. Sample collection and handling protocols are optimized to ensure maximum stability. Our teams are highly trained to process samples immediately post-collection, and we have established rigorous stability studies to validate our methods for long-term storage.

Q: What is the typical turnaround time for NHP studies, and what data formats will I receive?

A: Turnaround times vary depending on the study's complexity and scope. Our project management team will provide a detailed timeline at the outset. We deliver data in a variety of formats, including comprehensive study reports, raw data files, and summary presentations, all designed to be readily integrated into your regulatory submission packages.

Q: How do you compare the advantages of NHPs to other models, such as rodents or in vitro systems?

A: While in vitro systems and rodent models are valuable for early-stage screening, NHPs are a critical next step due to their closer genetic and physiological resemblance to humans. This allows for a more accurate assessment of a drug's safety and efficacy, particularly for complex systemic effects and gene therapy applications, significantly reducing the risk of unexpected results in human trials.

Contact Us

Creative Biolabs provides the expertise and infrastructure needed to navigate the complexities of biomedical development, delivering reliable data while upholding the highest ethical standards. Contact Our Team for More Information and to Discuss Your Project.